The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in parti…

Clostridium DifficileClostridium Difficile InfectionsClostridium Difficile Infection Recurrence+7 more

~Estimated

~$10 – $8,750

Vedanta Biosciences, Inc.NCT06237452

Phase 2

A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for Treatment and Reduction of Recurrent Clostridioides Difficile Infection in Patients With Multiple Recurrent Infections (IBZ-PATHFINDER)

Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).

Clostridium Difficile Infection Recurrence

~Estimated

~$10 – $8,750

Acurx Pharmaceuticals Inc.NCT07513285

Observational

Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile

The purpose of this study is to see if stool transplant performed by colonoscopy is effective at treating recurrent Clostridium difficile (C. diff) infection o…

Clostridium Difficile Infection RecurrenceClostridium Difficile Infection

~Estimated

~$10 – $7,500

Krunal PatelNCT03562741